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1108In Vitro Evaluation of Graft-versus-Graft Alloreactivity
as a Tool to Identify the Predominant Cord Blood Unit
before Double Cord Blood Transplantation
Antonia Moretta,1 Gabriella Andriolo,2 Daniela Lisini,1 Miryam Martinetti,3 Annamaria Pasi,3
Paolo Rebulla,2 Davide Soligo,4 Rosaria Giordano,2 Lorenza Lazzari,2 Rita Maccario1The transplantation of two cord blood (CB) units obtained from unrelated donors (double CBT) is an effec-
tive strategy for adult patients with hematologic malignancies. Sustained hematopoiesis after double CBT is
usually derived from a single donor, and only a few transplantation recipients displaying a stable mixed donor–
donor chimerism have been reported. We investigated the mechanisms underlying single-donor predomi-
nance in double CBT by studying in vitro the role of the graft-versus-graft cell-mediated immune effect in
two-way mixed-lymphocyte culture, along with the contribution of differential hematopoietic progenitor
(HP) potency in HP mixed cultures. Results for the two-way mixed-lymphocyte culture showed that despite
the weak and variable alloantigen-specific cytotoxic potential displayed by CBmononuclear cells, an immune-
mediated dominance for one of the two CB units was detected in the majority of experiments. Alloantigen-
induced cytotoxic activity was directed toward both CB-HP and phytohemagglutinin (PHA)-activated T
lymphoblastoid cells. The CB unit with the higher fold expansion of CD341 cells in single-expansion culture
was prevalent in the HP mixed-expansion culture, as shown by DNA chimerism evaluation. Based on these
data, we hypothesize that the dominant CB unit is able to develop prevalent cytotoxic activity toward acti-
vated lymphocytes of the other CB unit, thereby preventing them from exerting alloantigen-specific cytotoxic
potential against both activated lymphocytes and HPs of the dominant unit. In accordance with this hypoth-
esis, we propose the evaluation of alloantigen-induced cytotoxic activity generated in two-way mixed-
lymphocyte culture and directed toward PHA-activated T lymphoblastoid cells as a tool to identify the
potentially predominant CB unit before double CBT.
Biol Blood Marrow Transplant 18: 1108-1118 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Mixed-lymphocyte reaction, Cytotoxic lymphocyte, Hematopoietic progenitorINTRODUCTION
The infusion of two cord blood (CB) units ob-
tained from unrelated donors has been proposed as
a strategy for adult patients with life-threatening he-1Laboratory of Pediatric Immunology and Onco-Hema-
Transplant, Infant-Maternal Department Fondazione
S Policlinico San Matteo, Pavia, Italy; 2Cell Factory,
r of TransfusionMedicine, Cellular Therapy and Cryobi-
, Department of Regenerative Medicine, Fondazione
S Ca’ Granda Ospedale Maggiore Policlinico, Milano,
3HLA Laboratory, Transfusion Medicine Department,
zione IRCCS Policlinico San Matteo, Pavia, Italy; and
azione Matarelli, Milano, Italy.
iordano, Lorenza Lazzari, and Rita Maccario share senior
rship.
isclosure: See Acknowledgments on page 1117.
dence and reprint requests: Antonia Moretta, PhD, Fon-
e IRCCS Policlinico San Matteo, Plaza le Golgi 19,
Pavia, Italy (e-mail: a.moretta@smatteo.pv.it).
ugust 4, 2011; accepted December 28, 2011
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2011.12.586matologic diseases who are candidates for CB trans-
plantation (CBT), to overcome the limitation of low
cell dose present in a single CB unit [1-3]. Double
CBT has been shown to be effective after both
myeloablative and reduced-intensity conditioning reg-
imens [4-7]. In the majority of double CBTs, the two
CB units are partially HLA matched with the recipi-
ent, as well as with each other, and the use of two par-
tially HLA-matched CB units has been shown to
possibly reduce the risk of relapse in patients with leu-
kemia without increasing the risk of severe acute graft-
versus-host disease (aGVHD) [3,8-10].
Sustained hematopoiesis after double CBT is usu-
ally derived from transplantations involving a single
donor. Barker et al [4] reported that at 1 month after
transplantation, .70% of double CBT recipients dis-
played hematopoiesis from one CB unit, whereas by
day 100, 100% of patients displayed hematopoiesis
from a single donor. In contrast, other studies have
reported a state of stable mixed chimerism with contri-
butions from both CB units in some patients [6,11-13].
Gertow et al [14,15] recently reported two individuals
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after transplantation and showed that the two stableCB
units were phenotypically and functionally different
in terms of the number and secretome profile of T
and natural killer (NK) cells. It is conceivable that
a condition of stable mixed chimerism might be
favored by reduced-intensity conditioning regimens.
The biological mechanisms responsible for single-
donor predominance after double CBT remain incom-
pletely understood. Barker et al [4] suggested that
neither the total number of nucleated or CD341 cells
nor donor–recipient HLA disparity predicts which of
the two CB units will predominate; in contrast, the
predominant CB unit was found to contain a signifi-
cantly higher number of CD31 T lymphocytes. This
latter observation was not confirmed in an analysis of
a larger cohort of patients, however [1].
Preclinical studies suggested that an immune-
mediated effect could play a role in promoting the
predominance of one CB unit [16-18]. A recent study
documented that single CB unit dominance after
double CBT is concomitant with the presence of
a CD81 T cell response specific for the nonengrafted
CB unit in the peripheral blood of transplantation
recipients [12]. Moreover, an in vivo murine model
of double CBT that correlates with clinical engraft-
ment suggested that single-unit dominance is an
in vivo phenomenon likely associated with a graft-
versus-graft immune interaction [19]. However, the
number of postthaw granulocyte-macrophage col-
ony-forming units has been shown to be the only sig-
nificant factor predicting engraftment of the
predominating unit after double CBT [20].
In this context, we investigated an in vitro ap-
proach considered potentially suitable (and realisti-
cally applicable in a clinical setting) for predicting
the predominant CB unit before transplantation based
on the graft-versus-graft alloreactive potency. We
evaluated the possibility that an immune-mediated
mechanism is responsible for single CB unit predomi-
nance using a two-way mixed-lymphocyte culture
(MLC) approach. We also evaluated the potential sig-
nificance of the proliferation capacity of purified CB
CD341 hematopoietic progenitors (HPs) in determin-
ing the single CB unit predominance.MATERIALS AND METHODS
Experimental Design
Two in vitro culture approaches were optimized to
evaluate both the cell-mediated alloantigen-specific
graft-versus-graft immune response and the differen-
tial HP proliferation capacity of the CB units
(Figure 1). We evaluated the graft-versus-graft im-
mune response through primary and/or secondary
two-way MLCs in eight pairs of unrelated CB units.All pairs were HLA mismatched; this was formally
proven in three pairs of CB units tested in the two-
way MLC for which HLA genomic typing was
performed. Alloantigen-induced cytotoxic activity
generated in the two-way MLC was evaluated against
the target cells in phytohemagglutinin (PHA)-acti-
vated T lymphoblastoid cells (PHA-TLCs) and ex-
panded CB-HPs, target cells derived from the two
CB units assessed in the two-way MLC. We also eval-
uated the preferential proliferation capacity of each
CB unit in the two-wayMLC by analyzing microsatel-
lite DNA sequences (chimerism analysis).
To evaluate the differential HP potency of CB
units, we assessed three of the eight pairs of unrelated
HLA-mismatchedCBunits by expanding inmixed cul-
tures the purified CB CD34 HPs derived from the two
CB units used for the two-wayMLC.We evaluated the
preferential HP proliferation rate of each CB unit in
the mixed-culture expansion by chimerism analysis.
Collection of Human CB
Human CB from full-term newborns was collected
after obtaining written informed consent from the
mother. In detail, after delivery, the umbilical cord
was clamped and disinfected, and cells were collected
(with the placenta in utero) into sterile CB collection
bags containing 29 mL of citrate-phosphate dextrose
(Macopharma, Mouvaux, France) as an anticoagulant.
Freezing and Thawing of CB Cells
CB cells used for the ex vivo HP expansion were
processed within 24 hours of collection. The CB sam-
ples used in MLC experiments were cryopreserved
following our standard procedure (vol:vol) in 10%
DMSO (Cryoserv; Edward Lifesciences, Irvine CA)
and then thawed according to the method of
Rubinstein et al [21], as described previously [22]. Af-
ter cryopreservation and thawing, CB cell viability was
89.6% 6 11.08%.
CB CD341 Cell Selection
Human CB mononuclear cells (CBMCs) were iso-
lated by centrifugation after 1:3 (vol:vol) dilution with
phenol red-free RPMI 1640 (Sigma-Aldrich, Schnell-
dorf, Germany) and 2 mM EDTA (Sigma-Aldrich)
on a density gradient (Lympholyte-H, 1.077 g/mL;
Cedarlane, Ontario, Canada) at 1,600 rpm for 30 min-
utes at room temperature. The low-density cell frac-
tion was collected and washed twice with PBS
(Euroclone, Milan, Italy), 2 mM EDTA and 0.5% hu-
man serum albumin (Kedrion, Castelvecchio Pascoli
Barga, Italy) at 1,400 rpm for 10 min and at 800 rpm
for 10 min. Approximately 5  106 CBMCs were
used for the two-way MLCs; the remaining CBMCs
were incubated for 30 minutes with microbead-
conjugated anti-CD34 mAb (100 mL/108 cells;
Figure 1. Experimental design scheme. CBMCs were obtained from each CB unit pair (CB-A and CB-B). (A) In experiments 1-5, a portion of CBMCs
from eachCB unit were used to obtain PHA-TLCs, and the remaining portion was used to carry out primary and secondary two-wayMLCs. Effector cells
harvested from MLCs were tested for DNA chimerism, cell subset recovery, and alloantigen-specific cytotoxic activity toward both CB-A and CB-B
PHA-TLCs. (B) In experiments 6-8, a portion of CBMCs from each CB unit was used to select CD341 cells and perform single and mixed CB-HP ex-
pansion cultures and to obtain PHA-TLCs and carry out a secondary two-way MLC. Effector cells harvested from MLCs were tested for DNA chime-
rism, cell subset recovery, and alloantigen-specific cytotoxic activity toward both PHA-TLCs and expanded CB-HPs, and single and mixed CB-HP
expansion cultures were tested for DNA chimerism and cell subset recovery.
1110 Biol Blood Marrow Transplant 18:1108-1118, 2012A. Moretta et al.Miltenyi Biotec, Gladbach, Germany). CBCD341 cell
selection was then performed following the manufac-
turer’s instructions. The purity of selected CB
CD341 cells was evaluated by flow cytometry.In Vitro Expansion of CB CD341 Cells
CB CD341 cells were cultured for 2 weeks in
serum-free medium (CellGro SCGM;CellGenix, Frei-
burg, Germany) with IL-6 (10 ng/mL; PeproTech EC,
London, UK), stem cell factor (50 ng/mL; Endogen
Pierce,Rockford, IL), Flt-3 ligand (50ng/mL;Endogen
Pierce), thrombopoietin (10 ng/mL; PeproTech) and
10% heat-inactivated AB allogeneic plasma in cell cul-
ture chambers (Opticell; BioCrystal, Westerville, OH)
at 37Cand5%CO2 inhumidified air, as described pre-
viously [23]. The cytokines were added at the onset of
the culture and replaced twice each week. CD341 cells
obtained from twoHLA-mismatchedCBunitswere ex-
panded in single culture at a concentration of 5  103cells/mL and in mixed-expansion culture at a concen-
tration of 2.5 103 cells/mL for each sample (final con-
centration, 5  103 cells/mL). After in vitro single
culture or mixed- expansion culture procedures, CB-
HPs were harvested, manually counted, and character-
ized by flow cytometry.MLCs and Cytotoxicity Assays
MLCs were carried out with CBMCs from eight
pairs of unrelated CB units (CB-A, CB-B) or periph-
eral blood mononuclear cells (PBMCs) from five pairs
(PB-A, PB-B) of unrelated adult volunteers as controls.
Primary two-way MLC was performed as described
previously [24], by incubating a mixture of 5  104
CBMCs/microwell from each of the two units of the
pair. Recombinant IL-2 (5 U/mL, Proleukin; Chiron,
Emeryville, CA) was added to each well on days 13
and 16. Secondary two-way MLC was performed as
described previously [24,25], by adding 2.5  104
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subjects of the pair (stimulators) directly to the same
microwells of primary MLC effectors after 10 days of
primary two-way MLC, followed by recombinant
IL-2 (5 U/mL) on day 13. Primary and secondary
two-way MLCs were incubated for 10 and 8 days,
respectively and then tested in the cytotoxicity assay.
The same MLC procedures were carried out with
PBMCs from healthy unrelated adult individuals. T
and NK lymphocyte subset propagation was evaluated
by counting the numbers of CD31CD41 and
CD31CD81T cells/mL of culture, as well as the num-
ber of CD3/CD561 NK cells/mL of culture, recov-
ered after both primary and secondary two-way
MLC and comparing those values with the initial num-
bers (recorded on day 0). In addition, for each two-way
MLC experiment, one-way MLC, using CBMCs or
PBMCs from one of the two subjects of the pair as
responder cells and irradiated (3,000 cGy) CBMCs
or PBMCs of the other subject as stimulator cells,
was performed to evaluate the capacity of CBMCs or
PBMCs to generate alloantigen-specific cytotoxic
activity in the two-way MLC.
Alloantigen-specific cytotoxic activity was tested in
5-hour and 18-hour 51Cr-release assays as described
previously [24]. Results are expressed as lytic units
(LU)/106 effector cells, with 1 LU defined as the num-
ber of effector cells required to induce 10% lysis of
51Cr-labeled target cells (LU10). For some experi-
ments, results are expressed as percentage of lysis of
target cells [24]. 51Cr-labeled target cells included
PHA-TLCs, prepared as described previously [26]
and CB-HPs (see Experimental Design). PHA-TLCs
used as the target in cytotoxicity assays included
.95% T lymphocytes and \5% monocytes, B or
NK lymphocytes.
DNA Chimerism Analysis
DNAwas isolated fromCBMCs or PBMCs before
in vitro culture, from effector cells recovered after two-
way MLC, and from CB-HPs after mixed-expansion
culture. DNA chimerism was evaluated by microsatel-
lite analysis using a previously described polymerase
chain reaction (PCR)-based assay [27]. An initial
screening was carried out to identify an informative
marker for genotype discrimination of the two CB
units or PBMC samples of each analyzed pair. After
screening, at least two of the most informative short
tandem repeat loci for each pair were used for chime-
rism analysis.
Flow Cytometry Analysis
CB CD341-enriched cells and expanded CB-HPs
were washed and stained for 20 minutes at room tem-
perature in the dark with the followingmonoclonal an-
tibodies: CD34-PE, CD45-FITC, and 7AAD viabilitydye (Stem-Kit Reagents, Beckman Coulter, Fullerton,
CA). Cells labeled with CD45 FITC/isotypic control
PE and 7AAD viability dye were used as negative con-
trols. The cells were analyzed for the expression of the
following surfacemarkers: CD34-PE (BDBiosciences,
San Diego, CA), CD19-FITC (BD Biosciences),
CD61-FITC (BDBiosciences), CD56-PE (BDBiosci-
ences), CD133-APC (Miltenyi Biotec), CD3-APC
(Beckman Coulter), CD45 PC7 (Beckman Coulter),
and CD33-APC (BD Biosciences). After staining, the
cells were washed once with PBS containing 0.1%
BSA. At least 100,000 events were acquired with
a Cytomics FC500 flow cytometer (Beckman Coulter)
and analyzed using the CXP Analysis software.
Lymphocyte subsets were evaluated using FITC,
PE, PerCP, and PerCPCy5.5 mAbs specific for anti-
gens CD45, CD3, CD4, CD8, and CD56 (BD Biosci-
ences), with appropriate isotype-matched controls
(BDBiosciences). Two-color or three-color cytometry
by direct immunofluorescence with a FACSCalibur
flow cytometer (BD Biosciences) was performed as
described previously [28].HLATyping
Low-resolutionmolecular typing was used to char-
acterize HLA-A, -B, and -DRB1 loci, whereas the
HLA-C locus was typed using high-resolution PCR
amplification with sequence-specific primers [29].
DNA was isolated from blood specimens using mag-
netic beads and the robotic station that combines
aHamilton liquid handlingworkstationwithAGOWA
chemicals (Hamilton Robotics, Reno, NV). HLA-C
alleles were assigned using the sequence-specific
primers included in Pel Freez (Brown Deer, WI) and
Genovision (Vertriebsges, Austria) commercially
available kits. The amplified products were visualized
on 2% agarose gels and stained with 0.5 mg/mL of
ethidium bromide using the E-Gel Precast Agarose
Electrophoresis System (Invitrogen Life Technolo-
gies, Paisley, UK). This system essentially contains
all of the elements needed to perform electrophoresis
of DNA in a ‘‘ready-to-go’’ format.RESULTS
Cytotoxic Activity Induced in Two-Way MLCs
In a first set of experiments, five primary and/or
secondary two-wayMLCs (experiments 1-5) were car-
ried out, with CBMCs from five pairs of unrelated
HLA-mismatched CB units tested for alloantigen-
specific cytotoxic activity with PHA-TLCs as the
target. Evaluation of the cytotoxic capacity directed
against PHA-TLC targets, which were obtained
from CBMCs from each of the two CB units assessed
in the two-way MLC, revealed a dominant CB unit
Table 1. Tand NK Lymphocyte Subsets, Chimerism Status, and Cytotoxic Activity after Two-Way MLCs with CBMCs
Total Cells
T and NK Lymphocyte Subsetsa % DNA
Cytotoxicity versus PHA-TLC
Targetsb
T CD3+ T CD4+ T CD8+
NK
CD3neg CD56+ CB-A CB-B
CB-A PHA-TLC
Target
CB-B PHA-TLC
Target
Experiment 1: CB-1A + CB-1B
Day 0c 500 275 110 35 45 50 50
MLC I 350 280 105 171 49 40 60 1,111 0
MLC II 700 539 287 210 84 20 80 33 0
Experiment 2: CB-2A + CB-2B
Day 0 500 200 165 50 35 50 50
MLC I 220 99 ND 42 26 40 60 166 0
MLC II 110 96 45 36 7 20 80 333 0
Experiment 3: CB-3A + CB-3B
Day 0 500 315 225 65 120 50 50
MLC I ND ND ND ND ND ND ND ND ND
MLC II 280 224 165 28 8 10 90 166 0
Experiment 4: CB-4A + CB-4B
Day 0 500 355 335 60 20 50 50
MLC I 800 536 400 104 80 40 60 0 0
MLC II 140 70 62 11 14 30 70 0 0
Experiment 5: CB-5A + CB-5B
Day 0 500 350 100 85 55 50 50
MLC I 200 176 90 100 10 50 50 4,170 1,111
MLC II ND ND ND ND ND ND ND ND ND
Experiment 6: CB-6A + CB-6B
Day 0 500 385 270 60 40 50 50
MLC II 160 157 138 18 2 90 10 0 86
Experiment 7: CB-7A + CB-7B
Day 0 500 420 395 65 25 50 50
MLC II 200 168 ND 34 4 30 70 4,761 0
Experiment 8: CB-8A + CB-8B
Day 0 500 370 ND 70 30 50 50
MLC II 260 159 120 55 31 40 60 66 133
ND indicates not determined.
Primary (I) and secondary (II) two-way MLCs, performed with CBMCs from 8 pairs (CB-A, CB-B) of unrelated HLAmismatched CB units, are reported.
aResults expressed as cell number  103/mL.
bResults are expressed as lytic units/106 effector cells.
cDay 0 refers to CBMC-A and CBMC-B culture mix at the beginning of the culture.
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in experiments 1, 2, and 3, only one of the two PHA-
TLC targets was lysed (see representative experiment
2 in Figure 2A), whereas in experiment 5, both targets
were lysed, even though a predominant lysis of one of
the targets was observed (Figure 2B). Neither of the
two CB units used in experiment 4 showed detectable
cytotoxic activity. Results obtained from one-way
MLC, performed as a control for the respective two-
way MLC, showed that CB units 1B (experiment 1),
2A and 2B (experiment 2), 3B (experiment 3), and 5A
and 5B (experiment 5) had the capacity to lyse alloge-
neic stimulator PHA-TLCs used in theMLC, whereas
the remaining CB units did not have this capability
(data not shown). The two-way MLC cytotoxicity
data were also compared with data from experiments
using PBMCs from five pairs of healthy, unrelated
adult volunteers (Table 2). In this case, evaluation of
cytotoxic activity against PHA-TLC targets showed
dominance for one of the two adult donors in four
out of five experiments, whereas in one experiment,
both targets were consistently lysed, although a
predominant lysis of one of the two targets wasobserved (see the representative experiments shown
in Figure 2C and D). Control one-way MLCs docu-
mented a lytic capacity, directed toward the allogeneic
stimulators used in theMLC, of PBMCs from all adult
donors (data not shown).
CBMCs displayed slow killing kinetics in the cyto-
toxicity assays, with significant levels of lysis ($10%
specific lysis of the target) detectable only in the
18-hour 51Cr-release assay. Moreover, a suppressive
effect was detected in the majority of experiments
with CBMCs. Figure 3A shows how CB effector cells
usually exhibited greater cytotoxic activity at low effec-
tor:target (E:T) ratios. This observation suggests the
presence of suppressor cells within bulk cultures, the
activity of which is overrun by cytotoxic cells at low
E:T ratios. Compared with CBMCs, PBMCs ex-
hibited more rapid killing kinetics in the cytotoxicity
assay, with measurable levels of lysis already detectable
in the 5-hour 51Cr-release assay; no suppressive effect
was observed. A representative experiment is shown in
Figure 3B.
Chimerism analysis, performed on cells recovered
at the end of each two-way MLC, showed a greater
Figure 2. Alloantigen-specific cytotoxic activity generated in primary and secondary two-way MLCs. Cytotoxic activity was measured toward PHA-
TLC targets obtained fromCBMCs (A and B) or PBMCs (C and D) for each of the two subjects assessed in the two-way MLC. (A) Experiment 2: CB-2A/
CB-2B pair. (B) Experiment 5: CB-5A/CB-5B pair, primary MLC. Results from the secondary two-way MLC are not available because of the very low cell
recovery after primary culture that precluded the possibility of carrying out the assay. (C) Experiment 1: PB-1A/PB-1B pair. (D) Experiment 3: PB-3A/PB-
3B pair. Results are expressed as LU10/million effector cells. Dotted columns represent CB-A and PB-A targets; black columns, CB-B and PB-B targets.
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out of five experiments (Table 1). In experiments 1-3,
the prevalent CB unit in terms of DNA percentage was
also dominant in terms of alloantigen-directed
cytotoxic activity toward PHA-TLCs. The higher
DNA percentage for one of the two units in experi-
ment 4, in which no significant cytotoxic activity was
measured, conceivably can be explained by a greater
alloantigen-induced proliferation capacity of the CB-
4B unit compared with the CB-4A unit. Comparable
data were observed when chimerism analysis was per-
formed on cells recovered at the end of each primary
and/or secondary control two-way MLC performed
with PBMCs (Table 2).
Cell recovery and the lymphocyte subset distribu-
tion of two-wayMLC effectors are reported in Table 1
for CB units and in Table 2 for adult controls. In the
majority of both the CBMC and adult PBMC experi-
ments, the number of effector cells recovered from sec-
ondary two-way MLC was lower than the number of
input cells at day 0. These data do not agree with the
findings of the respective secondary one-way MLC,
in which effector cell propagation was 1.5- to
two-fold greater than the number of input cells in
CBMCs and two- to 2.5-fold greater than that in adult
PBMCs (data not shown). This observation suggests
that during the early phase of the two-way MLC, acti-
vated cytotoxic cells from each of the two units of the
pair killed cells from the other unit. As the culture pro-gressed, the unit with the prevalent alloantigen-
specific cytotoxic capacity overgrew the other unit.
In terms of effector cell phenotype, our data suggest
that CD81 cells, a population believed to include
mostly cytotoxic T lymphocytes, were preferentially
activated in two-way MLC carried out with adult
PBMCs (Table 2), whereas propagation of the same
subset was observed only infrequently when evaluating
CB effector cells in two-way MLC (Table 1). This ob-
servation could help explain the lower alloantigen-
specific cytotoxic potential developed in two-way
MLC by CBMCs compared with adult PBMCs.
In a second set of three CBMC experiments, effec-
tor cells recovered from secondary two-way MLC
were tested for cytotoxic capacity not only against
PHA-TLCs, but also against CB-HP targets. In all
three experiments, CB-HPs from both CB units were
lysed. Nonetheless, we observed a predominant
cytotoxic capacity toward CB-HPs of one of the two
CB units (Figure 4A-C). Simultaneous evaluation of
the cytotoxic activity toward PHA-TLC and HP
target cells showed concordance in the cytotoxic
prevalence for both CB-HP and PHA-TLC targets
in two of the three experiments (experiments 6 and 8;
Figure 4A and C). In experiment 7, we observed a pre-
dominant lysis of CB-7B-HP targets and a dominant
lysis of CB-7A PHA-TLC (Figure 4B). Chimerism
analysis performed in cells recovered at the end of
each two-way MLC revealed a higher percentage of
Table 2. Tand NK Lymphocyte Subsets, Chimerism Status, and Cytotoxic Activity after 2-Way MLCs with PBMCs
Total Cells
T and NK Lymphocyte Subsetsa % DNA
Cytotoxicity versus PHA-TLC
Targetsb
T CD3+ T CD4+ T CD8+
NK
CD3neg CD56+ PB-A PB-B
PB-A PHA-TLC
Target
PB-B PHA-TLC
Target
Experiment 1: PB-1A + PB-1B
Day 0c 500 380 210 115 45 50 50
MLC I 420 319 ND 281 50 40 60 1,111 0
MLC II 400 332 ND 316 16 30 70 1,111 0
Experiment 2: PB-2A + PB-2B
Day 0 500 385 210 95 60 50 50
MLC I 400 348 ND 276 28 30 70 111 8
MLC II 340 299 ND 282 3 10 90 333 0
Experiment 3: PB-3A + PB-3B
Day 0 500 350 220 95 80 50 50
MLC I 380 228 ND 87 137 50 50 74 166
MLC II 600 540 ND 222 24 50 50 0 0
Experiment 4: PB-4A + PB-4B
Day 0 500 375 220 115 40 50 50
MLC I ND ND ND ND ND ND ND ND ND
MLC II 600 360 174 186 180 90 10 3 28
Experiment 5: PB-5A + PB-5B
Day 0 500 325 135 110 70 50 50
MLC I ND ND ND ND ND ND ND ND ND
MLC II 550 451 198 286 77 10 90 476 0
ND indicates not determined.
Primary (I) and secondary (II) two-way MLCs performed with PBMCs from five pairs (PB-A, PB-B) of unrelated HLA-mismatched adult healthy donors
are reported.
aResults expressed as cell number  103/mL.
bResults expressed as lytic units/106 effector cells.
cDay 0 refers to PBMC-A and PBMC-B culture mix at the beginning of the culture.
1114 Biol Blood Marrow Transplant 18:1108-1118, 2012A. Moretta et al.DNA in one of the two CB units in all three experi-
ments (Table 1). In experiments 6 and 7, the prevalent
CB unit in terms of DNA percentage was also domi-
nant in terms of alloantigen-directed cytotoxic activity
toward PHA-TLC targets, whereas in experiment 8,
this type of concordance was not observed.
In these latter experiments, we also attempted to
evaluate the hypothesis that unidirectional NK allor-
eactivity [30-32] contributes to the predominance of
one of the two CB units. Potential NK alloreactivity
of each CB unit toward the other unit of the pair was
estimated on the basis of killer immunoglobulin-like
receptor (KIR) ligand expression, according to the
‘‘missing self-recognition’’ model (Table 3) [31,33].
In experiments 7 and 8, the pattern of unidirectional
potential NK alloreactivity was concordant with the
identification of the dominant CB unit in terms of
alloantigen-directed cytotoxic activity toward PHA-
TLC targets (Figure 4). We could not evaluate the
hypothesis that NK alloreactivity contributes to CB
unit dominance in experiment 6, because each CB
unit of the pair was potentially NK alloreactive toward
the other unit.
Proliferation and Phenotype of CB-HPs in
Mixed-Expansion Culture
In experiments 6-8, we evaluated the proliferation
capacity of CB-HPs in mixed-expansion culture by
culturing CB CD341 cells isolated from the same
CB units assessed in two-way MLC. The results, re-ported in Table 4, show that the median purity of
CB CD341 cells after immune selection at day 0 was
85% (range, 61%-94%), whereas the median fold ex-
pansions of total nucleated cells (TNCs) and CD341
cells in single- expansion culture were 261 (range,
119-349) and 19.4 (range, 9.5-33.4), respectively.
The expansion capacity of CB-HPs in mixed-
expansion culture was quite variable compared with
that of the same CB-HPs of the pair in single-
expansion culture. A prevalence of one CB unit over
the other in terms of DNA percentage was observed
in the three experiments with HP mixed-expansion
culture. In experiment 6, this observation could be
explained by the presence at day 0 of a higher percent-
age of CD341 cells in the prevalent CB unit (CB-6B)
compared with the other unit (CB-6A) at day 0. How-
ever, this explanation does not hold true for experi-
ments 7 and 8, in which the CD34 percentage at day
0 was identical. It is possible that one of the CB units
in experiments 7 and 8 had stronger stem cell potency.
In accordance with this hypothesis, we observed that
the prevalent CB units in terms of DNA percentage
also exhibited a greater capacity for CD341 cell expan-
sion (Table 4). Of note, the prevalent CB unit, in terms
of DNA percentage, identified in mixed-expansion
cultures of CB-HPs did not coincide with the preva-
lent CB unit, in terms of DNA percentage, detected
in two-way MLCs carried out with CBMCs from
the same pairs of CB units (experiments 6-8;
Tables 1 and 4).
Figure 3. Alloantigen-specific cytotoxic activity of secondary two-way
MLCs at different E:T ratios. Cytotoxic activity was measured toward
PHA-TLC targets obtained from CBMCs (A) or PBMCs (B) for each
of the two subjects assessed in the two-way MLC. (A) Experiment 3:
CB-3A/CB-3B pair. Black square, CB-3A PHA-TLC target; empty
square, CB-3B PHA-TLC target. (B) Experiment 2: PB-2A/PB-2B pair.
Black triangle, PB-2A PHA-TLC target; empty triangle, PB-2B PHA-
TLC target. Results are expressed as percent-specific lysis measured
in an 18-hour (CBMCs) or a 5-hour (PBMCs) 51Cr-release assay.
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in vitro expansionwas 7% (range, 5%-9%). Phenotypic
characterization of the CD341 cell subpopulation
revealed 71% (range, 70%-87%) CD1331 cells, 1.1%
(range, 1%-1.2%) CD38negCD33neg cells, and 15%
(range, 10%-23%) CD611 cells, demonstrating both
themaintenanceof amore immature stemcell compart-
ment and the presence of some already committed
megakaryocytic progenitors. The remaining CB-
CD34neg cells exhibited mainly a myeloid phenotype
(CD331). The proportion of contaminating lympho-
cytes was \1%, including CD31 T lymphocytes
(median, 0.3%; range, 0.19%-0.3%), CD191 B-
lymphocytes (median, 0.06%; range, 0-0.08%), and
CD561CD161 NK-lymphocytes (median, 0.1%;
range, 0.08%-0.5%). Moreover, no difference in im-
mune phenotype between the CB-HPs expanded in
single culture and mixed culture was observed.DISCUSSION
In the context of double CBT, several mechanisms
have been investigated to explain the biological inter-
actions between the two grafted CB units that causethe phenomenon of CB unit dominance, but a consen-
sus has yet to be reached [4,13,19,20,34]. In this article,
we describe a putative role for the two-way MLC as an
indicator of the dominant CB unit after double CBT.
Moreover, we show that the CB unit endowed with
the strongest HP potency in terms of CD341 prolifer-
ation capacity exhibits a greater capacity for extensive
growth of HP cells compared with its competitor in
the HP mixed-expansion culture.
In agreement with the results of seminal studies
that investigated fetal-maternal immune interactions
[35-37], our findings indicate that CBMCs have
weaker alloantigen-specific cytotoxic potential com-
pared with PBMCs from healthy adults and may
exert immunosuppressive activity. In particular, it
was previously shown that several CB T lymphocyte
subsets and CB monocytes may contribute to
the alloantigen-directed immunosuppressive effect
[35,37]. Nevertheless, despite the weak and variable
alloantigen-specific cytotoxic potential exhibited by
CBMCs, we observed an immune-mediated domi-
nance for one of the two CB units in the majority of
experiments.
Cytotoxic activity generated in two-way MLC was
directed toward both PHA-TLCs and in vitro ex-
panded CB-HPs. However, the latter were apparently
more susceptible to lysis mediated by effector cells
generated in two-way MLC. Indeed, CB-HPs from
both CB units of a pair were lysed, even though a prev-
alent cytotoxic capacity toward CB-HPs from one of
the two CB units was seen in all experiments. In con-
trast, one of the two CB units was strongly dominant
in the majority of experiments when PHA-TLCs,
a cell population including mainly activated T lym-
phocytes, served as the target cells.
In consideration of the observed patterns of cyto-
toxic activity mediated by CB effector cells emerging
in two-way MLC, we hypothesize that the predomi-
nant CB unit in the setting of double CBT is the
unit able to develop a prevalent cytotoxic activity
directed against activated lymphocytes of the other
CB unit, thus preventing them from exerting
alloantigen-specific cytotoxic potential against both
activated lymphocytes and HPs of the dominant unit.
The time needed for the predominant CB unit to over-
come the other unit in vivo could depend on the degree
of reciprocal alloantigen-specific cytotoxic potency of
the two CB units. Our preliminary data also suggest
that the potential NK alloreactivity of one CB unit
might contribute to the CB unit dominance in the dou-
ble CBT setting [30-32].
An advantage of our in vitro model is its ability to
simultaneously evaluate the proliferation rate of CB-
HPs derived from both single and double CB cultures.
In this system, the CB unit with the greater CD341
cell expansion rate in single culture was also the prev-
alent unit in the mixed-expansion culture. The
Figure 4. Alloantigen-specific cytotoxic activity generated in secondary two-way MLCs. Cytotoxic activity was measured toward both PHA-TLC and
expanded CB-HP targets obtained from CBMCs for each of the two subjects used in the two-way MLC. (A) Experiment 6: CB-6A/CB-6B pair. (B) Ex-
periment 7: CB-7A/CB-7B pair. (C) Experiment 8: CB-8A/CB-8B pair. Results are expressed as LU10/million effector cells. Dotted columns represent
CB-A PHA-TLC targets; black columns, CB-B PHA-TLC targets; striped columns, CB-A expanded HP targets; gray columns, CB-B expanded HP targets.
1116 Biol Blood Marrow Transplant 18:1108-1118, 2012A. Moretta et al.expansion rates obtained in the single-expansion cul-
tures were not predictive of those obtained in the co-
culture system. Several mechanisms potentially could
explain these results, including competition for the
administered growth factors due to a difference in
receptor number or activation state, inhibiting or stim-Table 3. HLATyping of CB Unit Pairs Used for Experiments 6-8
HLA-A HLA-B
Experiment 6: CB-6A + CB-6B
CB-6A 23, 31 35, 40
CB-6B 03, 68 35, 3502
Experiment 7: CB-7A + CB-7B
CB-7A 03, 24 13c, 51c
CB-7B 02, 03 50, 1517c
Experiment 8: CB-8A + CB-8B
CB-8A 02, 03 13c, 40
CB-8B 02, 68 44c, 55
aCw3 group.
bCW4 group.
cBw4 group.ulating paracrine mechanisms and cell–cell contact-
mediated effects. Our findings confirm recent reports
indicating that in the clinical setting of double CBT,
differential stem cell dose and potency may contribute
to the CB unit dominance [34,38]. It is conceivable
that the CB unit with the strongest HP potencyHLA-C HLA-DRB1
Potential NK Alloreactivity
(Missing Self)
0304a, 1203a 1001, 14 CB-6A versus CB-6B (cw3)
0401b, 0401b 07, 15 CB-6B versus CB-6A (cw4)
0202b, 0602b 07, 07
0602b, 0701a 07, 13 CB-7B versus CB-7A (cw3)
0304a, 0602b 01, 15 CB-8A versus CB-8B (cw4)
0303a, 160101a 07, 14
Table 4. Fold Expansion of TNC and CD34+ Cells and Chi-
merism Status after Mixed-Expansion Culture of Purified CB
CD34+ HPs
% CD34+ Cells
on Day 0
Fold
Expansion
TNC
Fold
Expansion
CD34+ Cells
% DNA
CB-A/CB-B
Experiment 6
CB-6A 61 119 29 ND
CB-6B 93 273 33, 4 ND
CB-6A + CB-6B ND 220 23, 4 30/70
Experiment 7
CB-7A 76 349 16, 5 ND
CB-7B 76 269 9, 5 ND
CB-7A + CB-7B ND 258 6, 2 80/20
Experiment 8
CB-8A 94 239 22, 3 ND
CB-8B 94 253 15, 5 ND
CB-8A + CB-8B ND 225 28, 7 70/30
TNC indicates total nucleated cells; ND, not determined.
Fold expansion refers to the number of cells recovered at the end of the
expansion culture with respect to the number of input cells at day 0. The
percentage of CD34+ cells at the beginning of mixed-expansion culture
of purified CB CD34+ HPs derived from the two subjects used for the
two-way MLC are reported; data achieved from single CB unit expan-
sion culture are also reported.
Biol Blood Marrow Transplant 18:1108-1118, 2012 1117Graft-versus-Graft Alloreactivity in Double CBTcould prevail in cases of absent immune dominance in
terms of graft-versus-graft alloreactivity.
Although alloantigen-reactive lymphocyte activa-
tion and CB-HP expansion conceivably are indepen-
dent phenomena, it is possible that a discordant
dominance between the two CB units, in terms of
stem cell potency and graft-versus-graft alloreactivity,
could be detrimental in the setting of double CBT, for
instance, when the dominant CB unit in terms of
alloreactive capacity eradicates the CB unit able to
support a more efficient hematopoietic engraftment.
Moreover, as emphasized by Gutman et al [12], the se-
lection of a potentially losing CB unit that shares host
antigens not present in the dominant CB unit (ie,
hematopoiesis-restricted minor histocompatibility
antigens [mHAgs] [39] or noninherited maternal anti-
gens [40]) is considered of paramount importance to
further enhance the graft-versus-leukemia effect of
double CBT [9,10] without increasing the risk of
severe GHVD.
Another advantage of our in vitro model is that it
allows evaluation of the interaction between the two
CB units in a nonperturbed system devoid of the im-
munologic influences of the recipient. However, it is
noteworthy that in the clinical setting of double
CBT, major histocompatibility complex (MHC) anti-
gens and/or mHAgs expressed by the recipient are ex-
pected to contribute to the activation of immune cells
of both CB units. Therefore, in the clinical setting, this
in vitro model might be adapted by adding irradiated
recipient PBMCs to also evaluate the contribution of
the MHC antigens and/or mHAgs on activation of
the immune cells present in CB units.
In conclusion, the results of our in vitro study con-
firm previously reported data [12-19] supporting thekey importance of graft-versus-graft cell-mediated al-
loreactivity as the principal mechanism promoting
the engraftment of a single CB unit in patients under-
going double CBT. The novel information provided
by our study is that two-way MLCmight be efficiently
applied in the evaluation of the potential graft-versus-
graft alloreactivity for predicting the dominant CB
unit before double CBT. We have set out an in vitro
experimental strategy that is now ready for validation
in a clinical setting to evaluate the predictive ability
of this approach.ACKNOWLEDGMENTS
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